- Home
- ODD vs PTCT Comparison
ODD vs PTCT Comparison
Compare ODD & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- PTCT
- Stock Information
- Founded
- ODD 2018
- PTCT 1998
- Country
- ODD Israel
- PTCT United States
- Employees
- ODD N/A
- PTCT N/A
- Industry
- ODD
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- ODD
- PTCT Health Care
- Exchange
- ODD Nasdaq
- PTCT Nasdaq
- Market Cap
- ODD 3.8B
- PTCT 5.3B
- IPO Year
- ODD 2023
- PTCT 2013
- Fundamental
- Price
- ODD $40.28
- PTCT $74.35
- Analyst Decision
- ODD Buy
- PTCT Buy
- Analyst Count
- ODD 11
- PTCT 17
- Target Price
- ODD $75.36
- PTCT $73.24
- AVG Volume (30 Days)
- ODD 846.3K
- PTCT 1.1M
- Earning Date
- ODD 11-19-2025
- PTCT 11-04-2025
- Dividend Yield
- ODD N/A
- PTCT N/A
- EPS Growth
- ODD 25.95
- PTCT N/A
- EPS
- ODD 1.80
- PTCT 8.94
- Revenue
- ODD $751,854,000.00
- PTCT $1,779,150,000.00
- Revenue This Year
- ODD $25.43
- PTCT $119.02
- Revenue Next Year
- ODD $20.18
- PTCT N/A
- P/E Ratio
- ODD $22.22
- PTCT $8.24
- Revenue Growth
- ODD 26.12
- PTCT 97.54
- 52 Week Low
- ODD $35.30
- PTCT $35.95
- 52 Week High
- ODD $79.18
- PTCT $73.99
- Technical
- Relative Strength Index (RSI)
- ODD 27.94
- PTCT 77.13
- Support Level
- ODD $38.60
- PTCT $69.23
- Resistance Level
- ODD $41.06
- PTCT $73.98
- Average True Range (ATR)
- ODD 2.01
- PTCT 2.64
- MACD
- ODD -0.13
- PTCT 0.32
- Stochastic Oscillator
- ODD 21.38
- PTCT 92.49
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.